Advanced Search

HCC2218 (ATCC® CRL-2343™)

Organism: Homo sapiens, human  /  Cell Type: Epithelial,lymphoblast  /  Tissue: mammary gland; breast/duct  /  Disease: TNM stage IIIA, grade 3,primary ductal carcinoma

Permits and Restrictions

View Restrictions
Organism Homo sapiens, human
Tissue mammary gland; breast/duct
Cell Type Epithelial,lymphoblast
Product Format frozen
Morphology epithelial
Culture Properties suspension, The cells grow as floating aggregates of large cell clusters.
Biosafety Level 1

Biosafety classification is based on U.S. Public Health Service Guidelines, it is the responsibility of the customer to ensure that their facilities comply with biosafety regulations for their own country.
Disease TNM stage IIIA, grade 3,primary ductal carcinoma
Age 38 years adult
Gender female
Ethnicity Caucasian, White
Storage Conditions liquid nitrogen vapor phase
Karyotype polyploid
Derivation
HCC2218 was derived from a female whose family members included several members with cancer; four lung cancer patients (two of them, non-smokers), two breast cancer patients (one of them also had lung cancer) and one colon cancer patient.
The HCC2218 cell line was initiated on April 10, 1996, and took 6 months to establish.
HCC2218 is a poorly differentiated cell line derived from the primary tumor of an invasive ductal carcinoma with metastases in 42/43 lymph nodes.
Clinical Data
38 years
Caucasian, White
female
Oncogene her2/neu +, p53 +
Genes Expressed
Epithelial glycoprotein 2 [EGP2]; cytokeratin 19
Cellular Products
Epithelial glycoprotein 2 [EGP2]; cytokeratin 19
Comments

The cells are highly positive for expression of Her2/neu, and are also positive for expression of p53. 

HCC2218 is positive for the epithelial cell specific marker Epithelial Glycoprotein 2 [EGP2] and for cytokeratin 19.

The cells are negative for expression of estrogen receptor (ER -).

An EBV transformed lymphoblastoid cell line [HCC2218 BL] from the same patient is available as ATCC CRL-2363.

The cells are highly positive for expression of Her2/neu, and are also positive for expression of p53.

Complete Growth Medium The base medium for this cell line is ATCC-formulated RPMI-1640 Medium, ATCC 30-2001. To make the complete growth medium, add the following components to the base medium: fetal bovine serum (ATCC 30-2020) to a final concentration of 10%.
Subculturing Cultures can be maintained by addition of fresh medium or replacement of medium. Alternatively, cultures can be established by centrifugation of the suspension with subsequent resuspension in fresh medium. Add medium as the cell density increases.

Medium Renewal: Add fresh medium every 2 to 3 days (depending on cell density).
Cryopreservation
Culture medium, 95%; DMSO, 5%
Culture Conditions
Temperature: 37°C
Name of Depositor AF Gazdar, AK Virmani
Year of Origin 1996
References

Gazdar AF, et al. Characterization of paired tumor and non-tumor cell lines established from patients with breast cancer. Int. J. Cancer 78: 766-774, 1998. PubMed: 9833771

Basic Documentation
Product Sheet
Product Sheet
Certificate of Analysis
Certificate of Analysis
SDS
SDS
Restrictions

The line is available with the following restrictions: 1. This cell line was deposited at the ATCC by Dr. Adi F. Gazdar and is provided for research purposes only. Neither the cell line nor products derived from it may be sold or used for commercial purposes. Nor can the cells be distributed to third parties for purposes of sale, or producing for sale, cells or their products. The cells are provided as service to the research community. They are provided without warranty of merchantability or fitness for a particular purpose or any other warranty, expressed or implied. 2. Any proposed commercial use of the these cells, or their products must first be negotiated with the University of Texas Southwestern Medical Center at Dallas, 5323 Harry Hines Blvd., Dallas, Texas 75235. Telephone (214) 648-1888, Email TechnologyDevelopment@UTSouthwestern.edu, or Fax: (214) 951-0935.
References

Gazdar AF, et al. Characterization of paired tumor and non-tumor cell lines established from patients with breast cancer. Int. J. Cancer 78: 766-774, 1998. PubMed: 9833771